Technical Analysis for SUPN - Supernus Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
B 38.29 0.39% 0.15
SUPN closed up 0.39 percent on Wednesday, February 8, 2023, on 1.16 times normal volume. It was able to find support at its 50 day moving average.
Earnings due: Feb 27
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Flat Down

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Fell Below 20 DMA Bearish 0.39%
New Downtrend Bearish 0.39%
50 DMA Support Bullish 0.39%
Wide Range Bar Range Expansion 0.39%
Multiple of Ten Bearish Other 0.39%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day about 11 hours ago
Up 2% about 11 hours ago
60 Minute Opening Range Breakout about 12 hours ago
Rose Above Lower Bollinger Band about 14 hours ago
Up 1% about 14 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Supernus Pharmaceuticals, Inc. Description

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of central nervous system diseases. Its products include SPN-538, an extended release topiramate product that completed clinical trials in support of new drug application for the treatment of epilepsy; Epliga, an extended release oxcarbazepine, which is in Phase III clinical trials targeting epilepsy; SPN-810, a molindone hydrochloride that is in Phase II clinical trials for treatment for impulsive aggression in patients with attention deficit hyperactivity disorder; and SPN-812, a Phase II clinical trial product targeting attention deficit hyperactivity disorder. The company also develops SPN-809, which has an open investigational new drug application for the treatment of depression. It intends to market its products to specialty physicians, including neurologists and psychiatrists in the United States. The company was founded in 2005 and is based in Rockville, Maryland.


Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Drug Discovery Clinical Trial Clinical Research Chloride Epilepsy Depression Neurology Attention Deficit Hyperactivity Disorder Clinical Trial Product Central Nervous System Disease Hyperactivity Disorder Investigational New Drug Treatment Of Depression Treatment Of Epilepsy Treatment Of Central Nervous System Diseases

Is SUPN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 42.09
52 Week Low 24.96
Average Volume 383,241
200-Day Moving Average 33.07
50-Day Moving Average 38.19
20-Day Moving Average 40.41
10-Day Moving Average 40.62
Average True Range 1.21
RSI 40.83
ADX 30.72
+DI 17.71
-DI 27.43
Chandelier Exit (Long, 3 ATRs) 38.45
Chandelier Exit (Short, 3 ATRs) 41.00
Upper Bollinger Bands 42.63
Lower Bollinger Band 38.18
Percent B (%b) 0.02
BandWidth 11.00
MACD Line 0.49
MACD Signal Line 0.92
MACD Histogram -0.4322
Fundamentals Value
Market Cap 2.02 Billion
Num Shares 52.7 Million
EPS 2.41
Price-to-Earnings (P/E) Ratio 15.88
Price-to-Sales 2.45
Price-to-Book 1.62
PEG Ratio 1.47
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 40.66
Resistance 3 (R3) 40.63 39.82 40.27
Resistance 2 (R2) 39.82 39.21 39.83 40.13
Resistance 1 (R1) 39.05 38.84 39.44 39.08 40.00
Pivot Point 38.24 38.24 38.43 38.25 38.24
Support 1 (S1) 37.47 37.63 37.86 37.50 36.58
Support 2 (S2) 36.66 37.26 36.67 36.45
Support 3 (S3) 35.89 36.66 36.32
Support 4 (S4) 35.92